Pain Therapeutics Inc. Stock Upgraded (PTIE)

NEW YORK ( TheStreet) -- Pain Therapeutics (Nasdaq: PTIE) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall.

Highlights from the ratings report include:
  • This stock has managed to rise its share value by 11.32% over the past twelve months. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 114.5% when compared to the same quarter one year prior, rising from -$0.21 million to $0.03 million.
  • PTIE, with its decline in revenue, underperformed when compared the industry average of 7.2%. Since the same quarter one year prior, revenues slightly dropped by 8.1%. Weakness in the company's revenue seems to not be hurting the bottom line, shown by stable earnings per share.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, PAIN THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$2.07 million or 163.32% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.

Pain Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel drugs. Its lead drug candidate is REMOXY painkiller, a novel controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes novel excipients. Pain has a market cap of $208.9 million and is part of the health care sector and drugs industry. Shares are up 22.9% year to date as of the close of trading on Friday.

You can view the full Pain Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Pfizer (PFE) Stock Falls After Dropping Pain Drug

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan